Conjugated linoleic acid reduces parathyroid hormone in health and in polycystic kidney disease in rats.
Feeding conjugated linoleic acid (CLA) is reported to reduce prostaglandin E(2) synthesis, which is required for parathyroid hormone (PTH) release.



This study was undertaken to determine whether CLA would suppress hyperparathyroidism and the resulting high-turnover bone disease in a rat model of polycystic kidney disease (PKD).



Outcome measurements were conducted after 8 wk of feeding diets supplemented with and without CLA (1% of dietary fat) to Han:SPRD-cy male rats (n = 52). PTH, bone formation, and resorption were assessed in addition to femur bone mass with use of dual-energy X-ray absorptiometry.



CLA feeding resulted in attenuation of PTH concentrations in both PKD-affected and nonaffected rats (by 60%) but did not significantly alter bone formation and resorption.



Reduction in PTH may open possibilities for CLA as an adjunctive therapy in secondary hyperparathyroidism.
Weiler
Hope
H
Department of Human Nutritional Sciences, University of Manitoba, Winnipeg, Manitoba, Canada. hweiler@ms.umanitoba.ca
Austin
Susan
S
Fitzpatrick-Wong
Shirley
S
Nitschmann
Evan
E
Bankovic-Calic
Neda
N
Mollard
Rebecca
R
Aukema
Harold
H
Ogborn
Malcolm
M
D015502:Absorptiometry, Photon; D000818:Animals; D001846:Bone Development; D001862:Bone Resorption; D004032:Diet; D005269:Femur / Q000503:physiopathology; D006961:Hyperparathyroidism / Q000150:complications / Q000503:physiopathology / Q000628:therapy; D044243:Linoleic Acids, Conjugated / Q000008:administration & dosage*; D008297:Male; D010281:Parathyroid Hormone / Q000097:blood*; D007690:Polycystic Kidney Diseases / Q000097:blood* / Q000150:complications / Q000503:physiopathology; D051381:Rats
D044243:Linoleic Acids, Conjugated; D010281:Parathyroid Hormone